Anlon Healthcare Q2 FY27 revenue doubles to INR 10,561.0 lacs as it builds integrated pharma platform
Q2 FY27 revenue up 102.3% to INR 10,561.0 lacs; PAT up 84.4% to INR 1,717.8 lacs; EBITDA margin 23.9% vs 26.3%.
By ScoutQuest · · 1 min read
- Q2 FY27 Revenue
- INR 10,561.0 lacs, up 102.3% YoY
- Q2 FY27 PAT
- INR 1,717.8 lacs, up 84.4%
- EBITDA Margin
- 23.9% vs 26.3%
- Period
- Q2FY27
- Positioning
- Anlon describes itself as an API and intermediates maker strong in niche NSAIDs, evolving into an integrated platform spanning chemicals, intermediates, APIs, formulations, biologics and medical devices.
📈 Q2 FY27 revenue from operations was INR 10,561.0 lacs, up 102.3% YoY, with PAT of INR 1,717.8 lacs, up 84.4%. H1 FY27 revenue of INR 19,317.2 lacs already exceeds FY26's INR 19,190.7 lacs. Margins compressed: Q2 gross margin 31.0% vs 36.9%, EBITDA margin 23.9% vs 26.3%.
📌 The company says it is moving from an API-focused NSAID manufacturer into an integrated platform, aided by the acquisitions of Apiqo, Bizotic and Anlon Medicos and new subsidiaries Anlon Biologics (peptides, biosimilars) and Anlon Medicare (surgical implants).
🏭 Management states growth will come from capacity expansion, CDMO commercialisation, new formulations and deeper vertical integration, and says it is targeting a materially higher export mix as DMF-backed products commercialise.
💰 Balance sheet: trade receivables rose to INR 14,275.3 lacs at Sep-26 from 10,367.8 lacs at Mar-26 and short-term borrowings to 6,167.3 lacs from 3,755.9 lacs; FY26 debt-to-equity is shown at 0.2x.
Also from Anlon Healthcare
Board approves unaudited Q2 results; auditor's review conclusion unmodified
29 Oct 2026
NSE, BSE give in-principle approval to 8,05,35,651-share preferential issue via share swap
29 Oct 2026
Anlon Healthcare to hold Q2 & H1 FY27 earnings call on 3 November 2026
26 Oct 2026
More numbers
- Revenue from operations, Q2 FY2710,561.0 (INR Lacs)
- Revenue growth YoY, Q2 FY27102.3%
- Profit after tax, Q2 FY271,717.8 (INR Lacs)
- PAT growth YoY, Q2 FY2784.4%
- EBITDA margin, Q2 FY2723.9%
- Revenue from operations, H1 FY2719,317.2 (INR Lacs)
- Profit after tax, H1 FY272,545.9 (INR Lacs)
- Revenue from operations, FY2619,190.7 (INR Lacs)
- Profit after tax, FY262,908.8 (INR Lacs)
- ROCE, FY2616.58%
- Trade receivables, Sep-2614,275.3 (INR Lacs)
- Short-term borrowings, Sep-266,167.3 (INR Lacs)
- Total equity, Sep-2629,555.7 (INR Lacs)
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.